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To investigate the characteristics of diﬀerent clinico-serologic subgroups of immune-mediated
necrotizing myopathy (IMNM).
Methods
We retrospectively reviewed data from medical charts of 64 patients diagnosed with IMNM
between 2012 and 2017 in 3 neuromuscular referral centers in The Netherlands and 1 in
Belgium.
Results
Seventeen patients had anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
autoantibodies (Abs), of whom 11 had a history of statin use, 15 had anti-signal recognition
particle (SRP) Abs, 2 had anti-melanoma diﬀerentiation-associated protein 5 (MDA5) Abs, 22
patients were seronegative, and 9 patients did not have a complete Ab assessment. Moderate to
severe disability in HMGCRAb–positive and anti-SRP Ab–positive IMNMwas common (71%
and 60%, respectively) despite multimodality treatment. Compared with statin-associated anti-
HMGCR Ab–positive IMNM, statin-naive anti-HMGCR Ab–positive IMNM patients were
more often men (67% vs 45%), had lower rates of dysphagia (17% vs 45%), and more
frequently had third-line therapy (50% vs 9%) and poor to fatal outcome (50% vs 0%).
Compared with seropositive IMNM, seronegative IMNM was characterized by female pre-
dominance (1:3), frequent occurrence of associated connective tissue disorders (22% vs 9%),
and signiﬁcantly higher rates of extramuscular disease activity (50% vs 16%, p 0.014; 2-sided
Fisher exact), also after excluding patients with an associated connective tissue disease (35% vs
7%, p 0.038; 2-sided Fisher exact).
Conclusions
Our ﬁndings indicate that seronegative IMNM forms a subgroup with distinctive features from
seropositive IMNM.
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A majority of patients with immune-mediated necrotizing
myopathy (IMNM)—a relatively new entity within the
spectrum of idiopathic inﬂammatory myopathies (IIMs)—
suﬀer from disability despite treatment, indicating inadequate
management.1–7 Indeed, disease management is complicated
due to the heterogeneity of IMNM. On the one hand, key
features of IMNM—i.e., progressive and often severe proximal
muscle weakness—are generally shared among patients.5,8 On
the other hand, disease manifestations such as dysphagia, axial
and respiratory muscle weakness, and cancer vary signiﬁcantly
between patients.1–9 No clear data exist with regard to the
variance in extramuscular disease activity (EMA) or associated
connective tissue diseases (CTDs) between diﬀerent patients
with IMNM.
Progress in further characterizing IMNM has been made by the
discovery of 2 myositis-speciﬁc autoantibodies (MSAs),
i.e., anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR) and anti-signal recognition particle (SRP) auto-
antibodies (Abs), which allowed for a serologic subclassiﬁcation
of IMNM.6,10 This has resulted in the identiﬁcation of 2 sub-
groups of patients with IMNM with distinct clinico-serologic
proﬁles. However, in a third of IMNM patients, these MSAs
cannot be detected in sera and are therefore called “seronega-
tive” IMNM.7 This group has not yet been characterized in
detail, except for an association with cancer.9 We conducted
a cross-sectional study to investigate clinical and serologic
characteristics in a case series of IMNM, including seronegative
IMNM, diagnosed in tertiary referral hospitals in The Neth-
erlands and Belgium.
Methods
Standard protocol approvals, registrations,
and patient consents
We retrospectively reviewed data from medical charts of
patients diagnosed with IMNM between 2012 and 2017 in 3
neuromuscular referral centers in The Netherlands and 1 in
Belgium. Diagnosis was based on the European Neuromus-
cular Centre criteria.7,11 Adult patients with subacute, sym-
metric, and predominantly proximal muscle weakness and
a muscle biopsy characterized by muscle ﬁber necrosis and
sparse to no inﬂammatory inﬁltrates were included. Toxic
myopathy, active endocrinopathy, amyloidosis, family history
of muscular dystrophy or proximal motor neuropathies, and
any histopathologic features characteristic of other IIM sub-
types were exclusion criteria. Furthermore, we excluded
patients with anti-synthetase syndrome.12 Muscle biopsies
(including immunostains) were re-evaluated in case of di-
agnostic uncertainty.7,11 The study was conducted in accor-
dance with the Declaration of Helsinki and the research codes
provided by the regional review board guidelines.
A predeﬁned set of data was extracted from the medical charts:
presence of MSAs and/or myositis-associated Abs (MAAs),
age at onset, sex, duration of follow-up, history of statin use,
the presence of proximal muscle weakness and dysphagia,
EMA, the presence of CTDs or cancer, serum creatine kinase
(CK) activity at diagnosis, treatment, and outcome. The fol-
lowing MSAs were assessed by a commercial semiquantitative
line blot essay (Euroimmun, Lubeck, Germany): anti-Mi2 α
and β, anti-transcriptional intermediary factor 1γ (TIF1γ),
anti-melanoma diﬀerentiation-associated protein 5 (MDA5),
anti-nuclear matrix protein 2 (NXP2), anti-small ubiquitin-like
modiﬁer activating enzyme 1 (SAE1), anti-histidyl-tRNA
synthetase (Jo1), anti-SRP, anti-threonyl-tRNA synthetase
(PL7), anti-alanyl-tRNA synthetase (PL12), anti-glycyl-tRNA
synthetase (EJ), and anti-isoleucyl-tRNA synthetase (OJ). On
the same line blot assay, the following MAAs were assessed:
anti-Ku, anti-polymyositis-scleroderma 100 protein (PM-
Scl100), anti-polymyositis-scleroderma 75 protein (PM-
Scl75), and anti-Ro52.13 A negative or a weak titer (1+) was
considered negative, whereas moderately elevated (2+) and
high titers (3+) were considered positive. In addition, anti-
HMGCR Abs were assessed by a commercial quantitative
enzyme-linked immunosorbent assay (ELISA; INOVA, San
Diego, CA).14 A level of anti-HMGCR Abs of 20 units/mL or
higher was considered positive. The participating centers used
the same line blot and anti-HMGCR assays. Patients were
subsequently serologically grouped as follows: (1) anti-
HMGCR Ab–positive IMNM, further subclassiﬁed in statin-
associated and statin-naive disease; (2) anti-SRP Ab–positive
IMNM; (3) IMNM with MSAs other than anti-HMGCR or
anti-SRP Abs; (4) seronegative IMNM in case no MSAs were
found; and (5) IMNMwith incomplete serologic status in case
serum could not be analyzed by both the line blot essay and the
quantitative anti-HMGCR ELISA. If a patient had a combi-
nation of MSAs and MAAs, the patient was classiﬁed into the
respective MSA subgroup. EMA included interstitial lung
disease (ILD), arthritis, Raynaud phenomenon, and skin or
cardiac symptoms if considered IIM related.15 An associated
CTDwas considered present if a formal diagnosis of CTDwas
established at any time during the disease. Cancer was con-
sidered disease related if present from 3 years before to 3 years
Glossary
Ab = autoantibody; CK = creatine kinase; CTD = connective tissue disease; DM = dermatomyositis; EMA = extramuscular
disease activity; HMGCR = hydroxy-3-methylglutaryl-coenzyme A reductase; IIM = idiopathic inﬂammatory myopathy;
IMNM = immune-mediated necrotizing myopathy; ILD = interstitial lung disease; IVIg = intravenous immunoglobulin;
MAA = myositis-associated Ab; MSA = myositis-speciﬁc autoantibody; SLE = systemic lupus erythematosus; SRP = signal
recognition particle; SSc = systemic sclerosis; ULN = upper limit of normal.
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after a diagnosis of IMNM.9 Serum CK activity was expressed
as the number of times the upper limit of normal (ULN) of the
local laboratory. The ULN for serum CK activity of the Dutch
laboratories was 145 IU/L for women and 171 IU/L for men,
and in the Belgian laboratory, this was 170 IU/L for women
and 195 IU/L for men. Treatment was scored as follows: (1)
glucocorticoid monotherapy; (2) second-line therapy con-
sisting of azathioprine and/ormethotrexate and/or calcineurin
inhibitors and/or mycophenolate mofetil; and (3) third-line
therapy consisting of intravenous immunoglobulins (IVIgs),
cyclophosphamide, rituximab, or other biologicals. Outcome
was deﬁned as good to excellent in case of normal or near-
normal functioning (with no apparent disability), moderate in
case of slight to moderate disability (e.g., use of cane), poor in
case of severe disability (e.g., wheelchair-bound), or dead.
Statistical methods
Results were primarily described using simple descriptive
statistics. In addition, statistical tests for comparison of clini-
cally relevant disease characteristics between seropositive and
seronegative patients were performed, consisting of a Mann-
Whitney U test for age and a 2-sided Fisher exact test for sex,
the presence of dysphagia, EMA, associated CTDs, the use of
third-line treatment, and favorable outcome. The explorative
nature of this study did not allow for multiple comparisons.16
Data availability
Any data not published within the article will (after anonym-
ization) be shared on request from any qualiﬁed investigator.
Results
In total, 64 patients were included: 33 from Amsterdam, 16
from Ghent, 12 from Nijmegen, and 3 from Leiden. In 1
patient, the diagnosis was based on the presence of anti-
HMGCR Abs without pathologic conﬁrmation. All other
patients had undergone a muscle biopsy showing necrotizing
myopathy with no or minimal lymphocytic inﬁltrates.
Seventeen patients (27%) had anti-HMGCR Abs, of whom
eleven (65%) had a history of statin use. Fifteen patients (23%)
had anti-SRP Abs, of whom 1 patient (7%) also had another
MSA (anti-MDA5) and 3 patients (20%) also hadMAAs (anti-
Ro52 Abs, anti-polymyositis-scleroderma-75 [PM-SCl75] Abs,
and anti-Sjo¨gren syndrome-A Abs, respectively). One patient
(2%) had anti-MDA5 Abs only. Twenty-two patients (34%)
had noMSAs, of whom 4 (18%) hadMAAs: 2 anti-Ku Abs, one
anti-Ro52 Ab, and one anti-PM-Scl75 Ab. Nine patients (14%)
had incomplete Abs data: data on myositis line blot assay and
anti-HMGCRAbs ELISAwere not available in 7 and 2 patients,
respectively. These 9 patients were excluded from further
analysis. The demographics and disease characteristics of the
remaining 55 patients are shown in table 1.
Median age at onset was 54 years (range 16–82), and 33
patients (61%) were women. The age at onset of patients with
seronegative IMNM (median age 51 years, range 16–79 years)
was comparable to that of patients with anti-SRP Ab–positive
IMNM (median age 49 years, range 20–82 years), but lower
than that of patients with HMGCR Ab–positive IMNM
(median age 60 years, range 54–74 years). No statistical sig-
niﬁcant diﬀerence in age between seropositive and seronega-
tive patients (p 0.189; Mann-Whitney U test) was found.
Female preponderance was observed in seronegative IMNM
(M:F ratio 1:3) compared with patients with seropositive
IMNM (M:F ratio 1:1). This ﬁnding did not reach statistical
signiﬁcance (p 0.158; 2-sided Fisher exact test). Median
follow-up was 2 years (range 1 week to 24 years). The patient
with a 1-week follow-up died of respiratory weakness and
myocardial infarction. In total, 5 patients had a follow-up
duration of less than 1 year.
All patients presented with proximal muscle weakness con-
sisting of upper arm and upper leg weakness (legs more than
arms), except 1 patient who had only proximal leg weakness.
Dysphagia was present in 21 patients (38%). Compared with
statin-associated HMGCR Ab–positive (45%) and anti-SRP
Ab–positive (53%) IMNM, dysphagia was found less fre-
quently in statin-naive anti-HMGCR Ab–positive (17%)
IMNM and seronegative (27%) IMNM. No statistical sig-
niﬁcant diﬀerence in the prevalence of dysphagia between
seropositive and seronegative patients (p 0.262; 2-sided
Fisher exact test) was found.
EMA and associated CTDs were found predominantly in se-
ronegative IMNM. Eight patients (15%) of whom 5 (67%)
with seronegative IMNM had an associated CTD. Four
patients had systemic sclerosis (SSc), 2 patients mixed CTD, 1
patient systemic lupus erythematosus (SLE), and 1 patient
SLE and Sjo¨gren’s syndrome. EMA was found in 11 patients
(50%) with seronegative IMNM compared with 5 patients
(16%) with seropositive IMNM, respectively (table 1). A
statistical signiﬁcant diﬀerence in the occurrence of EMA
(p 0.014; 2-sided Fisher exact test) but not in CTDs (p 0.248;
2-sided Fisher’s exact) between seropositive and seronegative
patients was demonstrated, also after excluding 8 patients with
an associated CTD (p 0.038; 2-sided Fisher exact test).
Among all included patients, the most frequent EMA features
included arthritis in 6 (11%), Raynaud phenomenon in 5
(9%), and ILD in 4 (7%). ILD was found in 3 patients (14%)
with seronegative IMNM and in 1 patient (6%) with anti-
HMGCR Ab–positive IMNM. None of the patients had
classical skin abnormalities consistent with dermatomyositis
(DM), i.e., heliotropic erythema or Gottron papules. Related
cancers were found in 5 cases (9%), equally distributed among
the subgroups. Related cancers included larynx carcinoma,
ovary carcinoma, mediastinal tumor, bladder carcinoma, and
breast carcinoma.
Median serum CK activity was 41 times the ULN, ranging
from normal to 300 times the ULN. There was 1 patient with
normal serum CK activity presenting with rapidly progressive
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muscle weakness and polyarthritis, who had a muscle biopsy
consistent with IMNM, no MSAs/MAAs, and responded
favorably to glucocorticoid therapy. Diﬀerences in median
serum CK activity did not diﬀer between the 3 IMNM
subgroups.
Eleven patients (20%) received glucocorticoid monotherapy,
whereas 28 (51%) and 14 (25%), respectively, had second-
and third-line treatment (table 2). Treatment data were not
available for 2 patients (4%). Third-line therapy, mostly IVIg,
was administered to 50% of the statin-naive anti-HMGCR
Ab–positive IMNM patients and 55% of the anti-SRP Ab–
positive IMNM patients, as compared to 10% of the statin-
associated anti-HMGCR Ab–positive IMNM patients and
15% of seronegative IMNM patients. We found no statistical
signiﬁcant diﬀerences in the rates of third-line treatment be-
tween seropositive and seronegative patients (p 0.200; 2-sided
Fisher exact test).
Twenty-one patients (38%) had good to excellent outcome,
26 patients (47%) had moderate outcome, 3 patients (5%)
had poor outcome, and 4 patients (7%) died (table 2). Out-
come data were not available in 1 patient (2%). Causes of
deaths included laryngeal carcinoma, metastasized bladder
carcinoma, renal failure, and a mediastinal tumor. Except for
the small group of statin-naive anti-HMGCR Ab–positive
IMNM patients, of whom 3 (50%) had a poor outcome or
died, outcome was essentially the same across the other
subgroups. We found no statistical signiﬁcant diﬀerences in
the rates of good-excellent outcomes between seropositive
and seronegative patients (p 0.397; 2-sided Fisher exact test).
Discussion
We found that seronegative IMNM had distinctive features
including a signiﬁcantly higher frequency of EMA. The higher
rates of EMA in seronegative IMNM were not fully explained
by the concomitant presence of an associated CTD, thus
indicating a truly distinctive feature. A female predominance
and higher rates of associated connective tissue disorders were
seen in seronegative patients, but these ﬁndings did not reach
statistical signiﬁcance, probably due to the relatively small
sample size. One study found higher rates of cancer in sero-
negative IMNM compared with the HMGCR Ab–positive
and anti-SRP Ab–positive IMNM.9We could not conﬁrm this
in our study, again probably because of the relatively small
sample size of our study. It may well be that the female pre-
ponderance has to be ascribed to the association with CTDs
as was the case in two-thirds of the seronegative patients. SSc
was the most frequent CTD in these patients. A recent study
found that necrotizing myopathy was the second most
Table 1 Demographics and disease characteristics of 55 patients with an IMNM












Age at onseta (median years, range) 63 (54–74) 57 (52–65) 49 (20–82) 47 51 (16–79)
Femalesa (n, %) 5 (45) 2 (33) 8 (53) 1 (100) 16 (73)
Disease features
Proximal muscle weakness (n, %) 11 (100) 6 (100) 15 (100) 1 (100) 21 (95)
Dysphagiaa (n, %) 5 (45) 1 (17) 8 (53) 1 (100) 6 (27)
CK (median deviation from ULN, range) 64 (6–114) 90 (4–176) 59 (18–195) 4 30 (0–83)
Extramuscular diseaseb activity (n, %) 1 (9) 1 (17) 3 (20) 0 (0) 11 (50)
CTDa,c (n, %) 0 (0) 1 (17) 2 (13) 0 (0) 5 (22)
MAAs (n, %) 0 (0) 0 (0) 3 (20) 0 (0) 4 (18)
Cancer (n, %) 1 (9) 1 (17) 1 (7) 0 (0) 2 (9)
Abbreviations: anti-MDA5 = anti-melanoma differentiation-associated protein 5 Ab–positive IMNM; anti-SRP = anti-signal recognition particle Ab–positive
IMNM; CK = serum creatine kinase activity; CTD = connective tissue disease; IMNM= immune-mediated necrotizingmyopathy;MAA =myositis-associated Ab;
seronegative = IMNM without any myositis-specific Ab; statin +ve anti-HMGCR = statin-associated anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)
autoantibody (Ab)-positive IMNM; statin −ve anti-HMGCR = statin-naive anti-HMGCR Ab-positive IMNM; ULN = upper limit of normal.
a The differences in age, sex, and the presence of dysphagia or associated CTDs between seropositive and seronegative patients were not statistically
significant.
b Interstitial lung disease, arthritis, Raynaud phenomenon, and skin or cardiac symptoms if considered myositis related. The difference in the prevalence of
EMA between seropositive and seronegative patients was statistically significant (16% vs 50%, p 0.014; 2-sided Fisher exact test), also after excluding patients
with an associated connective tissue disease (7% vs 35%, p 0.038; 2-sided Fisher exact test).
c Five patients with systemic sclerosis, 3 patients with mixed connective tissue disease, 1 case with systemic lupus erythematosus (SLE), and 1 case with both
SLE and Sjo¨gren syndrome.
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common histologic subtype (according to the 2004 ENMC
criteria) in patients with SSc.17
Of note, 2 patients had anti-MDA5 Ab–positive IMNM.
These antibodies are associated with classic DM or overlap
myositis with other cutaneous manifestations, frequent oc-
currence of prominent ILD, and relatively little myositis.5,18
The patient with solely anti-MDA5 Abs has been previously
described and had no skin rash or ILD.19 The patient with
both anti-SRP and anti-MDA5 Abs presented with proximal
muscle weakness, nonspeciﬁc skin erythema on her chest and
upper arms, digital cutaneous ulceration, arthralgia, and a se-
rum CK activity of 90 times the ULN. This concomitant
presence of 2 MSAs is remarkable because usually, MSAs are
mutually exclusive.4,6,20
We found some apparent diﬀerences when we compared our
seropositive patients with those reported in previous reports.
Although earlier reports did not ﬁnd any diﬀerences between
statin-associated and statin-naive anti-HMGCR Ab–positive
IMNM except for younger age at onset, higher serum CK
activity, and more frequent non-Caucasian ethnicity in the
latter, we observed that statin-naive anti-HMGCR Ab–
positive IMNM patients were more often men (66% vs 45%),
had lower rates of dysphagia (17% vs 46%), received more
often third-line therapy (50% vs 9%), and had more fre-
quently poor to fatal outcome (50% vs 0%).6 The number of
cases with a history of statin use in anti-HMGCR–positive
IMNM (65%) was comparable to that found in North
American and European case series with HMGCR Ab–
positive IMNM (44%–67%) and much higher as compared to
a Japanese case series with HMGCR Ab–positive IMNM
(18%).1,2,6 None of our anti-SRP Ab–positive IMNMpatients
had ILD, although an association in 13%–22% has been
reported.1,3,4 The frequency of cancer in our patients was too
low to compare it with that of other case series. Our data
conﬁrm that in general, HMGCR Ab–positive IMNM and
anti-SRP IMNM are severe conditions, as illustrated by the
proportion of patients (65%) with moderate, severe, or fatal
outcome despite multimodality treatment.1–4,6
The strength of our study is the detailed description of the
IMNM group as a whole, and in particular with respect to the
description of the as yet relatively underexposed seronegative
patients. The main limitation of our study is the retrospective
nature and the relatively small sample size of the study.
Our ﬁndings indicate that seronegative IMNM is distinct from
seropositive IMNM, given the frequent occurrence of EMA
and associated CTDs and the female preponderance in the
former. The results may not necessarily be extrapolated to
other ethnic populations, considering the predominantly
European ancestry of our study population. Larger pro-
spective studies are warranted to conﬁrm our ﬁndings.
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Table 2 Treatment and outcome in 55 patients with an immune-mediated necrotizing myopathy (IMNM)






(n = 22)Statin +ve (n = 11) Statin 2ve (n = 6)
Treatmenta
Glucocorticoid monotherapy (n, %) 2 (18) 1 (17) 3 (20) 0 (0) 5 (23)
Second-line therapy (n, %) 8 (73) 2 (33) 5 (33) 1 (100) 12 (54)
Third-line therapy (n, %) 1 (9) 3 (50) 7 (47) 0 (0) 3 (14)
Outcomeb
Good-excellent outcome (n, %) 4 (36) 1 (17) 6 (35) 0 (0) 10 (45)
Moderate outcome (n, %) 7 (63) 2 (33) 8 (57) 1 (100) 8 (36)
Poor outcome (n, %) 0 (0) 2 (33) 0 (0) 0 (0) 1 (5)
Dead (n, %) 0 (0) 1 (17) 1 (7) 0 (0) 2 (9)
Abbreviations: anti-MDA5 = anti-melanoma differentiation-associated protein 5 Ab–positive IMNM; anti-SRP = anti-signal recognition particle Ab–positive
IMNM; seronegative = IMNM without any myositis-specific Ab; statin +ve anti-HMGCR = statin-associated anti-3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) autoantibody (Ab)-positive IMNM; statin −ve anti-HMGCR = statin-naive anti-HMGCR Ab-positive IMNM.
a Treatment schemes of patients with IMNM shown in percentages. Treatment data from 2 (9%) patients with seronegative IMNM are missing; azathioprine
and/or methotrexate and/or mycophenolatemofetil were considered second-line therapy; intravenous immunoglobulins (n = 13) and/or rituximab (n = 3; all
in combination with intravenous immunoglobulins) and/or cyclofosfamide (n = 1) were considered third-line therapy. Differences in the rates of third-line
treatment between seropositive and seronegative patients were not statistically significant.
b Outcomes in IMNM shown in percentages. Outcome data from 1 (5%) patient with seronegative IMNM is missing; good-excellent outcome was defined as
normal or near-normal functioning with no apparent disability; moderate outcome was defined as slight to moderate disability (e.g., use of cane); poor
outcome was defined as severe disability (e.g., wheelchair-bound); causes of deaths included laryngeal carcinoma, metastasized bladder carcinoma,
pneumonia, respiratory weakness and myocardial infarction, peritonitis, and a mediastinal tumor. Differences in the rates of good-excellent outcomes
between seropositive and seronegative patients were not statistically significant.
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